![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Estrogen-receptor positive breast cancer accounts for 75% of diagnosed breast cancers worldwide. There are currently two major options for adjuvant treatment: tamoxifen and aromatase inhibitors. Variability in metabolizing enzymes determines their pharmacokinetic profile, possibly affecting treatment response. Therefore, prediction of therapy outcome based on genotypes would enable a more personalized medicine approach, providing optimal therapy for each patient. In this review, the authors will discuss the current evidence on the most important metabolizing enzymes in endocrine therapy, with a special focus on CYP2D6 and its role in tamoxifen metabolism.
Financial & competing interests disclosure
This work was supported by the Federal Ministry for Education and Research (BMBF), Germany (grants 03IS2061C and 01ZP0502), the IZEPHA grant 21-0-0 and the Robert Bosch Foundation, Stuttgart, Germany. PH Saladores is a fellow of FP7 EU Marie Curie Initial Training Network FightingDrugFailure (GA238132) and JC Precht is a fellow of the Hans L Merkle Stiftung, Germany. H Brauch and M Schwab report that they have initiated scientific collaborations in 2009 with Roche Molecular Diagnostics and Siemens Healthcare Diagnostics Products GmbH, respectively. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.